4arthritisinfo.co.uk Rotating Header Image

Posts on ‘April 8th, 2009’

Stem cells used to relieve dog’s arthritis pain (Asbury Park Press)

Nine-year-old Higgins lay on the operating table, as doctors bustled around him, preparing for surgery to relieve him of the arthritis pain in his hips.

New drug shows promising results for psoriatic arthritis (EurekAlert!)

( Wiley-Blackwell ) Psoriatic arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor ? (anti-TNF?) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic arthritis. Golimumab is a new human monoclonal antibody that works against TNF? and has been shown to be beneficial within two weeks of the [...]

Bad Mix Of Bacterial Remnants And Genetics Leads To Arthritis (Science Daily)

Here’s another reason to hate leftovers. A new study sheds light on one cause of arthritis: bacteria. In the study, scientists from the United States and The Netherlands show that a specific gene called NOD2 triggers arthritis or makes it worse when leftover remnants of bacteria cell walls, called muramyl dipeptide or MDP, are present.

Genetic risk factors play role in autoantibody-negative rheumatoid arthritis (EurekAlert!)

( Wiley-Blackwell ) During the past few years, several new genetic risk factors for rheumatoid arthritis (RA) have been identified. The majority of genetic risk factors identified so far have been associated with autoantibody-positive RA, which affects about two-thirds of RA patients, but distinguishing this variant from autoantibody-negative RA, which is less destructive, is considered [...]

New drug shows promising results for psoriatic arthritis (PhysOrg)

Psoriatic arthritis affects about 11 percent of patients with psoriasis. Anti-tumor necrosis factor ? (anti-TNF?) agents, which block signaling molecules that induce inflammation, improve the symptoms of psoriatic arthritis. Golimumab is a new human monoclonal antibody that works against TNF? and has been shown to be beneficial within two weeks of the first subcutaneous injection [...]